MitoQ

FOXO exclusively licenses epigenetic clocks from UCLA

Latest articles

Drive to end cancer could pioneer diagnostic technology

Blood test that can determine a cancer signal origin with high accuracy is now available on prescription in the US and could lead to...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

Improving speed and accuracy in Alzheimer’s patients

Phase 2a study of patients with Alzheimer's or Parkinson's finds that ANVS401 treatment leads to significant improvement in speed and accuracy. Annovis Bio Inc, a...

New SIRT6 activator supplement hits the market

Sirtuin 6, the protein making waves in the longevity pool, can now be activated by a brand-new supplement. SIRT6 is a protein with an important...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...
fundraising

Editor's picks

Drive to end cancer could pioneer diagnostic technology

Blood test that can determine a cancer signal origin with high accuracy is now available on prescription in the US and could lead to...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

Improving speed and accuracy in Alzheimer’s patients

Phase 2a study of patients with Alzheimer's or Parkinson's finds that ANVS401 treatment leads to significant improvement in speed and accuracy. Annovis Bio Inc, a...
MitoQ

Click the globe for translations.

FOXO Technologies’ exclusive licence of epigenetic clocks PhenoAge and GrimAge from UCLA could be an insurance game-changer.

FOXO Technologies Inc has announced the licence of two epigenetic clocks, PhenoAge and GrimAge, for use in the prediction of human mortality in the life insurance industry. These licences, in addition to the Epigenetic Mortality Predictor, give FOXO the exclusive usage of epigenetic clocks developed by Dr Steve Horvath for the financial services industry.

Longevity.Technology: Your genes might be set in stone, but your epigenome – the chemical markers that sit above your DNA and switch genes on and off – changes throughout your life depending on diet, exposure to toxins (alcohol, smoking, pollution, &c), stress, exercise and disease. These lifestyle and environmental factors cause methylation, a process where methyl groups become attached to the genes, influencing which ones are switched on or off.

DNA and epigenomes can be easily sequenced with saliva tests, and the number of methyl groups is an indicator of previous lifestyle choices and – hello there, insurance companies – a predictor of future health and even lifespan. Predicting actual biological age, rather than calendar years is clearly something the insurance industry could use; rather than underwriting and policy pricing being based on actuarial data, life insurance could be personalised and dependent on year-on-year choices. It would be rather like those car insurance policies that are based on your mileage; if you run your car or body into the ground, it’ll cost you, both financially and physically.

FOXO uses AI, epigenetics and cutting-edge bioinformatics tools to develop and commercialise epigenetic biomarkers of health and aging. FOXO says it sees broad application for its proprietary biomarker technology for insurers, health researchers and life science companies. Securing the additional licences give FOXO a competitive advantage in its mission to modernise life insurance through FOXO LIFE.

FOXO LIFE seeks to reimagine the role life insurance plays in the health of its customers through a state-of-the-art health and wellness platform with “Life insurance designed to keep you alive”™.

 


 

“The discoveries made by Dr Horvath are astounding and irrefutable as to defining the relationship between measurable molecular changes in our biology and aging.

 


 

“The epigenetic clocks developed by Dr Steve Horvath are the gold standard in understanding biological aging,” said Jon Sabes, CEO and Founder of FOXO. “The discoveries made by Dr Horvath are astounding and irrefutable as to defining the relationship between measurable molecular changes in our biology and aging.”

Steve Horvath
Dr Steve Horvath: Professor in Human Genetics and Biostatistics at UCLA and inventor of the Horvath Clock.

Featured on the cover of Nature Magazine in April 2014, biomathematician Dr Steve Horvath was dubbed “The Clock-Watcher” when he reported the discovery of a strikingly accurate way to measure human aging through epigenetics. What has developed since is a consensus that epigenetic clocks conclusively measure aspects of our biology that relate to aging and mortality.

Slowing aging

In addition, Dr Horvath’s research has shown that anti-aging longevity research can better focus on how to slow or even reverse the aging process by stabilising epigenetic changes, which can be reversible.

FOXO recently announced closing of its first external funding of $10 million, bringing the total to $40 million of funding secured to date, to support its core mission to modernize life insurance with molecular biotechnology.

Images courtesy of FOXO and Dr Steve Horvath

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
MitoQ

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
fundraising

Related articles

Calling all longevity start-ups and scale-ups

Some news from us! Longevity.Technology's brand-new investment portal brings innovators and investors together. As a part of our mission to support the companies that will...

Occuity – shining a light on health and longevity

Forget windows to the soul, Occuity's non-invasive smart diagnostic tech provides a window to health and wellness. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited)...

Workforce wellbeing platform scales up

Digital twin platform syd gets deployed by NHS, closes first workplace wellbeing deal in US and kicks off independent studies. DISCLOSURE: Longevity.Technology (a brand...

PCL Health embarks on preventive care trial with NHS

PCL Health enables preventive care by driving actionable insights from a wide range of health data. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Wyss Center gets CE mark for NeuroKey brain-AI interface

The Wyss Center announces CE mark for its brain-computer interface software for communication, NeuroKey BCI, which enables communication in real time. The Wyss Center, which...
MitoQ